Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Disorders of the Hepatic and Mesenteric Circulation Full Text available with Trip Pro

Disorders of the Hepatic and Mesenteric Circulation ACG Clinical Guideline: Disorders of the Hepatic and Mesente... : American Journal of Gastroenterology ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800 (...) Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance

2020 American College of Gastroenterology

2. Diagnosis and Management of Autoimmune Hepatitis Full Text available with Trip Pro

Diagnosis and Management of Autoimmune Hepatitis Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases - Mack - - Hepatology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Search term PRACTICE GUIDELINE Free Access Diagnosis and management of autoimmune hepatitis in adults (...) Library Terms and Conditions of Use. Shareable Link Use the link below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on Abstract The objectives of this document are to provide guidance in the diagnosis and management of autoimmune hepatitis (AIH) based on current evidence and expert opinion, and to present guidelines to clinically relevant questions based on systematic reviews of the literature and the quality of evidence (1). This practice

2020 American Association for the Study of Liver Diseases

3. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

4. Givosiran (Givlaari) - acute hepatic porphyria

Givosiran (Givlaari) - acute hepatic porphyria Drug Approval Package: GIVLAARI (givosiran)Injection U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GIVLAARI (givosiran)Injection Company: Alnylam Pharmaceuticals Inc. Application Number: 212194 Approval Date: 11/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

5. Using exome sequencing in the diagnosis of hepatic glycogen storage disease patients: a systematic review of the literature

Using exome sequencing in the diagnosis of hepatic glycogen storage disease patients: a systematic review of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

6. Efficacy and safety of direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in children and adolescents: a systematic review and meta-analysis

Efficacy and safety of direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in children and adolescents: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2020 PROSPERO

7. Effect of infection by the hepatitis-B virus on sperm parameters: a systematic review and meta-analysis

Effect of infection by the hepatitis-B virus on sperm parameters: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

8. Practice Advisory: Hepatitis B Prevention

Practice Advisory: Hepatitis B Prevention Practice Advisory: Hepatitis B Prevention - ACOG Menu ▼ Practice Advisory: Hepatitis B Prevention Page Navigation ▼ Share: Practice Advisory: Hepatitis B Prevention The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) have released updated guidance on preventing the transmission of hepatitis B virus (HBV) infection (1). A critical element of the strategy to eliminate HBV in the United States (...) is the prevention of perinatal transmission. The CDC and ACIP’s updated guidance reflects the best currently available evidence and select new or updated recommendations include the following: Pregnant women positive for hepatitis B surface antigen (HBsAg) should be tested for hepatitis B virus deoxyribonucleic acid (HBV DNA) to guide the use of antiviral medication to prevent perinatal transmission Persons with chronic liver disease* should be vaccinated against HBV The American Association for the Study

2019 American College of Obstetricians and Gynecologists

9. Hepatitis B: the green book, chapter 18

Hepatitis B: the green book, chapter 18 Hepatitis B: the green book, chapter 18 - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis B: the green book, chapter 18 Hepatitis B immunisation information (...) for public health professionals. Published 20 March 2013 Last updated 18 November 2019 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details is an infection of the liver caused by the hepatitis B virus (HBV). Published 20 March 2013 Last updated 18 November 2019 18 November 2019 Removed previous

2019 Public Health England

10. Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus

Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Carfilzomib (Kyprolis▼): risk (...) of reactivation of hepatitis B virus Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib. Published 21 November 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: hepatitis B virus reactivation has been reported in patients treated with carfilzomib screen all patients for hepatitis B virus before initiation of carfilzomib; patients with unknown serology who are already

2019 MHRA Drug Safety Update

11. Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Glecaprevir/Pibrentasvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A19-33 Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-33 Version 1.0 Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) 11 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Glecaprevir/pibrentasvir (chronic hepatitis C

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents

Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents Final Appraisal Recommendation Advice No: 1319 – October 2019 Glecaprevir/pibrentasvir (Maviret ® ) 100 mg/40 mg film-coated tablets Limited submission by AbbVie Ltd. Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (...) as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to < 18 years. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Final

2019 All Wales Medicines Strategy Group

13. Is routine nasogastric decompression after hepatic surgery necessary? A systematic review and meta-analysis Full Text available with Trip Pro

Is routine nasogastric decompression after hepatic surgery necessary? A systematic review and meta-analysis Currently the nasogastric tube (NGT) is routinely inserted in clinical after abdominal surgery for decompression in China, yet the practice varies between regions, the role of NGT for the patients after hepatic surgery remains unclear. Therefore, this present meta-analysis aimed to assess the efficacy and safety of NGT placement after hepatic surgery.A systematic review and meta-analysis (...) DATA SOURCES: PUBMED, EMBASE, Science Direct, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI) and Wanfang Database (until Mar 30, 2019) were systematically searched.Randomized controlled studies (RCTs) comparing the efficacy and safety of NGT and no NGT treatment after hepatic surgery were included. Data were synthesized using a random-effects or fixed effect model according to the heterogeneity. Outcomes were presented as Mantel-Haenszel style odd

2019 EvidenceUpdates

14. Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy

Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy '); } else { document.write(' '); } ACE | Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Search > > Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy - Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Rifaximin 550 mg tablet as add (...) -on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy. Subsidy status Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

15. Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C

Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C Search > > Direct-acting antiviral agent for treating genotype 2 to 6 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C First published on 2 January 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration: 12 weeks' treatment of sofosbuvir/velpatasvir for patients with genotype 2 to 6 hepatitis C virus without cirrhosis or with compensated cirrhosis (Child

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

16. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes (Abstract)

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin, improving subcutaneous insulin's hepatic biodistribution. We assessed HDV-insulin lispro (HDV-L) versus insulin lispro (LIS) in type 1 diabetes (T1D).Insulin Liver Effect (ISLE-1) was a 26-week, phase 2b, multicenter, randomized, double-blind, noninferiority trial.Among 176

2019 EvidenceUpdates

17. Antivirals for adults with recent onset (acute) hepatitis C

Antivirals for adults with recent onset (acute) hepatitis C NHS England » Antivirals for adults with recent onset (acute) hepatitis C Search Search Menu Antivirals for adults with recent onset (acute) hepatitis C Document first published: 26 September 2019 Page updated: 26 September 2019 Topic: Publication type: NHS England will routinely commission antivirals for adults with acute hepatitis C (HCV), including the treatment of acute HCV infection in immunosuppressed adults (e.g. post

2019 NHS England

18. Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents

Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents Published 11 November 2019 1 Product update SMC2214 glecaprevir/pibrentasvir 100mg/40mg film-coated tablets (Maviret®) AbbVie Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated (...) submission glecaprevir/pibrentasvir (Maviret®) is accepted for use within NHSScotland. Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years. SMC has previously accepted glecaprevir/pibrentasvir for the treatment of chronic HCV infection in adults. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir/pibrentasvir. This advice is contingent upon the continuing

2019 Scottish Medicines Consortium

19. Hepatitis E: health protection response to reports of infection

Hepatitis E: health protection response to reports of infection Hepatitis E: health protection response to reports of infection - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote (...) in the General Election on 12 December. Guidance Hepatitis E: health protection response to reports of infection Guidance on low public health risk, surveillance process and follow up with contacts. Published 14 June 2012 Last updated 8 November 2019 — From: Documents Ref: PHE publications gateway number: GW-698 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you

2019 Public Health England

20. Norovirus and hepatitis A virus scheme: recent intended results

Norovirus and hepatitis A virus scheme: recent intended results Norovirus and hepatitis A virus scheme: recent intended results - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote (...) in the General Election on 12 December. Guidance Norovirus and hepatitis A virus scheme: recent intended results This proficiency testing (PT) scheme is suitable for laboratories that examine viruses in food products or waters using molecular methods. Published 31 July 2017 Last updated 5 November 2019 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us

2019 Public Health England